PT2670401E - Métodos de utilização de inibidores de alk - Google Patents

Métodos de utilização de inibidores de alk Download PDF

Info

Publication number
PT2670401E
PT2670401E PT127036705T PT12703670T PT2670401E PT 2670401 E PT2670401 E PT 2670401E PT 127036705 T PT127036705 T PT 127036705T PT 12703670 T PT12703670 T PT 12703670T PT 2670401 E PT2670401 E PT 2670401E
Authority
PT
Portugal
Prior art keywords
methods
alk inhibitors
alk
inhibitors
Prior art date
Application number
PT127036705T
Other languages
English (en)
Portuguese (pt)
Inventor
Nanxin Li
Jennifer L Harris
Peter Mcnamara
Fangxian Sun
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2670401(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2670401E publication Critical patent/PT2670401E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT127036705T 2011-02-02 2012-02-02 Métodos de utilização de inibidores de alk PT2670401E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02

Publications (1)

Publication Number Publication Date
PT2670401E true PT2670401E (pt) 2015-10-12

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127036705T PT2670401E (pt) 2011-02-02 2012-02-02 Métodos de utilização de inibidores de alk

Country Status (22)

Country Link
US (1) US8703787B2 (enExample)
EP (1) EP2670401B1 (enExample)
JP (1) JP5837095B2 (enExample)
KR (1) KR101521861B1 (enExample)
CN (1) CN103458881B (enExample)
AU (1) AU2012212142B2 (enExample)
BR (1) BR112013019643B1 (enExample)
CA (1) CA2824092C (enExample)
CY (1) CY1116662T1 (enExample)
DK (1) DK2670401T3 (enExample)
EA (1) EA023404B1 (enExample)
ES (1) ES2543567T3 (enExample)
HR (1) HRP20150946T1 (enExample)
HU (1) HUE025395T2 (enExample)
ME (1) ME02200B (enExample)
MX (1) MX2013008791A (enExample)
PL (1) PL2670401T3 (enExample)
PT (1) PT2670401E (enExample)
RS (1) RS54189B1 (enExample)
SI (1) SI2670401T1 (enExample)
SM (1) SMT201500300B (enExample)
WO (1) WO2012106540A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
AU2013341271A1 (en) * 2012-11-07 2015-05-14 Novartis Ag Combination therapy
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) * 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
JP6510510B2 (ja) * 2013-07-11 2019-05-08 ベータ ファーマシューティカルズ カンパニー リミテッド プロテインチロシンキナーゼモジュレーター及び使用方法
US20160361314A1 (en) * 2013-08-28 2016-12-15 Novartis Ag Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
AU2014372166B2 (en) * 2013-12-23 2017-10-26 Novartis Ag Pharmaceutical combinations
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
US10053458B2 (en) * 2014-06-17 2018-08-21 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
CN106220644B (zh) 2015-04-24 2020-07-31 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技(苏州)有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
SG11201901251SA (en) * 2016-08-29 2019-03-28 Univ Michigan Regents Aminopyrimidines as alk inhibitors
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
ATE542801T1 (de) * 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
WO2008007368A2 (en) 2006-07-10 2008-01-17 Rf Dynamics Ltd. Food preparation
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009233964B2 (en) * 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
EA201391114A1 (ru) 2013-12-30
CA2824092C (en) 2020-06-30
AU2012212142A1 (en) 2013-08-15
ME02200B (me) 2016-02-20
JP2014504646A (ja) 2014-02-24
CA2824092A1 (en) 2012-08-09
DK2670401T3 (en) 2015-09-07
EP2670401B1 (en) 2015-06-10
KR20130121174A (ko) 2013-11-05
JP5837095B2 (ja) 2015-12-24
HUE025395T2 (en) 2016-02-29
US20130296357A1 (en) 2013-11-07
CN103458881B (zh) 2015-08-12
BR112013019643B1 (pt) 2022-04-19
CN103458881A (zh) 2013-12-18
WO2012106540A1 (en) 2012-08-09
AU2012212142B2 (en) 2015-09-24
RS54189B1 (sr) 2015-12-31
SMT201500300B (it) 2016-01-08
BR112013019643A2 (pt) 2016-10-04
PL2670401T3 (pl) 2015-11-30
SI2670401T1 (sl) 2015-10-30
HRP20150946T1 (hr) 2015-10-09
MX2013008791A (es) 2013-10-07
EA023404B1 (ru) 2016-05-31
CY1116662T1 (el) 2017-03-15
US8703787B2 (en) 2014-04-22
EP2670401A1 (en) 2013-12-11
KR101521861B1 (ko) 2015-05-21
ES2543567T3 (es) 2015-08-20

Similar Documents

Publication Publication Date Title
SI2670401T1 (sl) Postopki uporabe inhibitorjev ALK
EP2665725A4 (en) BICYCLIC ALK HEMMER
IL232358A0 (en) Inhibitors of phosphodiesterase type 10a
AP3907A (en) 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
HRP20260473T1 (hr) Metoda generiranja rekonstruiranog bloka
EP2596675A4 (en) METHODS OF MANAGING MULTIPLE TIME ADVANCE GROUPS
ZA201309532B (en) Inhibitors of t-cell activation
ZA201307496B (en) Novel rock inhibitors
EP2675458A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201206456B (en) Uses of dgati inhibitors
SG11201400102WA (en) Inhibitors of nedd8-activating enzyme
EP2776393A4 (en) NAMPT INHIBITORS
IL231353A0 (en) New enzyme inhibitory compounds
GB201114854D0 (en) Novel rock inhibitors
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201114798D0 (en) Method of modifying surfaces
EP2879681A4 (en) INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
HK1191649A (en) Bicyclic inhibitors of alk
HK1191648A (en) Bicyclic inhibitors of alk
GB201120474D0 (en) Inhibitors
GB201104399D0 (en) Novel inhibitors
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors